Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myostatin x Activin A Bispecific
- Development stage
- Preclinical
- Lead developer
- iBio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
The Myostatin x Activin A Bispecific antibody is an early-stage therapeutic candidate developed by iBio for the treatment of obesity and cardiometabolic diseases. Developed using an AI-integrated platform, this bispecific antibody is designed to simultaneously inhibit Myostatin (GDF-8) and Activin A. Both targets are members of the TGF-beta superfamily that act as negative regulators of skeletal muscle mass. By dual-targeting these pathways, the therapy aims to promote fat loss while preserving or increasing lean muscle mass, potentially overcoming the muscle-wasting limitations associated with current weight-loss treatments like GLP-1 receptor agonists. The candidate is currently in the discovery and optimization phase.
- Other names
- Myostatin/Activin A bispecific antibodyiBio Myostatin x Activin A Bispecific
02
Targets
GDF11 (Growth differentiation factor 11)GDF8 (Myostatin)Activin A
Beyond the preview
Go deeper on Myostatin x Activin A Bispecific.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myostatin x Activin A Bispecific.